Fibroscan / VCTE Rate-of-Change Interpretation: Normal Range, Optimal Targets, and MASLD Staging

What the Test Actually Measures

Fibroscan (made by Echosens) is the most widely used device for VCTE. The probe sends a 50-Hz mechanical pulse into the liver and uses ultrasound to time how fast the resulting shear wave travels through tissue. Stiffer tissue, generally reflecting more fibrous collagen, propagates the wave faster. The result is reported in kilopascals, a unit that has been correlated against biopsy-confirmed fibrosis stage in multiple validation cohorts.

The same exam simultaneously reports the Controlled Attenuation Parameter (CAP, in dB/m), which estimates hepatic steatosis from ultrasound attenuation. A single 10-minute session therefore yields two separate numbers: a fibrosis estimate (kPa) and a steatosis estimate (dB/m).

VCTE's original validation work was done largely in chronic hepatitis C, not MASLD. The Ziol et al. cohort (N=327 patients with chronic hepatitis C) showed that liver stiffness correlated with biopsy fibrosis stage, with reported area-under-curve values that varied by the specific stage comparison being made.[1] Later work extended elastography validation to metabolic liver disease, which is the relevant population for most readers of this page, but the reader should keep in mind that not every numeric cutoff in circulation traces back to a MASLD-specific cohort.

Technical validity requirements

A VCTE result is only interpretable when the interquartile range-to-median ratio (IQR/M) is below 0.30. This threshold appears in FDA device labeling and in the EASL Clinical Practice Guidelines on non-invasive tests.[2] If IQR/M is at or above 0.30, the exam should be repeated, ideally after a 2-hour fast and after the patient has rested supine for about 10 minutes.

Readings can be pushed upward by factors that have nothing to do with structural fibrosis: active hepatic inflammation (an ALT well above the upper limit of normal), right-sided heart failure with hepatic congestion, and recent food intake. Reviewing same-day ALT before interpreting a borderline result is a reasonable habit.

CAP alongside kPa

EASL's 2021 guidance describes three CAP bands: below 248 dB/m (minimal steatosis), 248 to 267 dB/m (moderate steatosis), and 268 dB/m or above (severe steatosis).[2] A patient can have a normal kPa and a high CAP at the same time, which represents steatosis without significant fibrosis yet. That pattern still supports lifestyle and metabolic intervention even when no fibrosis-specific treatment is indicated.

Normal Range and Fibrosis Stage Cutoffs

Guideline bodies do not use one single universal cutoff table; EASL's 2021 non-invasive test guidance and the AASLD 2023 practice guidance on MASLD converge on similar but not identical staging ladders.[2,3] The ranges below reflect that convergence, and a reader comparing them to a specific lab report should confirm which threshold set that report is using.

F0-F1: no or minimal fibrosis

Liver stiffness below roughly 7.0 kPa is generally read as F0 (no fibrosis) or F1 (mild fibrosis) in MASLD patients without active hepatitis.[3] This does not rule out steatosis or inflammation; a MASLD activity score can be elevated even with a reassuring kPa. A stable low-risk patient at this stage is typically re-tested at 24 months.

F2: significant fibrosis

A cutoff around 8.0 kPa is used as a "rule-in" threshold for roughly F2 disease. EASL's 2021 guidance pairs this cutoff with other non-invasive markers such as FIB-4 rather than relying on VCTE alone.[2] Patients in this range benefit from closer metabolic follow-up and, depending on trajectory, specialist referral.

F3: advanced fibrosis

A reading at or above roughly 12.0 kPa in a MASLD patient without confounding inflammation is generally consistent with F3 (bridging fibrosis).[3] This is also the stage at which patients begin to meet the biopsy-based eligibility criteria that support resmetirom prescribing, discussed below. Diagnostic performance at this threshold has been reported in the 0.8-plus AUROC range across several validation studies, though the exact figure depends heavily on which cohort and reference standard is used; a reader relying on a specific decimal AUROC for a specific study should verify it against that study directly rather than treat it as a fixed universal number.

F4: cirrhosis

Values at or above roughly 13.0 to 15.0 kPa are read as probable cirrhosis, with guidelines differing on the exact cutoff.[2] Multiple meta-analyses have reported good discrimination for VCTE in detecting cirrhosis, generally in a similar high-0.8s AUROC range, but a precise pooled figure and its confidence interval should be pulled from the specific meta-analysis being cited rather than restated as a fixed constant, since figures vary by probe type, population, and reference standard. Patients at this stage need hepatology co-management, variceal surveillance by endoscopy, and periodic hepatocellular carcinoma (HCC) surveillance with ultrasound and AFP.

Rate-of-Change Interpretation: What Counts as Meaningful Movement

A single kPa number is informative on its own, but the more decision-relevant question for a patient already diagnosed with MASLD is usually how that number is trending. "Rate of change" refers to the percentage shift in liver stiffness between two adequately valid exams taken at a defined interval, and it is where VCTE adds the most value beyond a one-time snapshot.

A single VCTE reading tells you where the liver stiffness stands today; a pair of valid readings a year apart, with confounders like recent alcohol, a fatty meal, or an ALT flare accounted for, tells you whether fibrosis is likely moving in the wrong direction. EASL's non-invasive test guidance treats a rise of about 20% or more in liver stiffness over roughly 12 months as a signal worth acting on, and a fall of about 30% or more over 12 to 18 months as evidence consistent with fibrosis regression, though neither threshold is a diagnosis on its own and both should be interpreted alongside ALT and FIB-4.[2]

What the trial evidence adds

Trials in MASLD and NASH have used liver stiffness change as a secondary endpoint alongside paired biopsy. In the resmetirom MAESTRO-NASH trial (biopsy-confirmed MASH with F2-F3 fibrosis), a larger proportion of resmetirom-treated patients achieved at least one stage of fibrosis improvement without worsening MASH compared with placebo, a difference reported as statistically significant.[11] The exact percentage split by dose reported in secondary sources varies slightly depending on which analysis is cited; a reader who needs the precise trial numbers for a clinical decision should confirm them against the FDA label or the original New England Journal of Medicine publication rather than a secondhand summary.[10,11]

Other trials, including obeticholic acid and semaglutide programs in MASH, have reported that patients whose liver stiffness fell during treatment were more likely to also show histologic fibrosis improvement on paired biopsy, supporting VCTE as a reasonable (though imperfect) non-invasive proxy for biopsy change during treatment.[6,12] The specific multiplier used to describe how much more likely histologic improvement is when LSM falls varies by trial and should not be treated as a universal constant across drugs or populations.

Decision framework: what to do with a rate-of-change result

This framework is meant to structure the conversation between a serial VCTE result and a clinical decision. It does not replace biopsy, FIB-4, or specialist judgment, and it assumes both exams met the IQR/M <0.30 validity check.

Exception to the whole table: if the two compared exams differ in fasting state, probe type (M vs XL), or time of day, treat the "change" as unreliable regardless of percentage, and repeat both measurements under matched conditions before acting on the trend.

Confounders that mimic progression or regression

An apparent rise in kPa can happen without any real fibrosis change if the patient ate within 2 hours of the exam, drank alcohol in the prior 24 hours, or has an ALT flare from any cause. A 20% rise alongside a marked ALT elevation is more consistent with acute inflammation than structural progression, and repeating the exam after ALT normalizes usually resolves the ambiguity.

Weight change is the other major confounder. Meaningful weight loss lowers liver stiffness partly through reduced steatosis and hepatic congestion, independent of any change in fibrous tissue itself. A bariatric surgery follow-up study reported liver stiffness reductions alongside fibrosis regression on paired biopsy at longer-term follow-up, though the exact cohort size and magnitude reported in secondary summaries should be checked against the original Lassailly et al. publication before being cited as a fixed number.[7] Semaglutide-driven weight loss produces a broadly similar pattern; the STEP 1 trial reported substantial mean body weight reduction with once-weekly subcutaneous semaglutide 2.4 mg over roughly a year of treatment, which is the kind of change that can independently move a liver stiffness reading.[8]

Re-testing intervals by stage

AASLD's 2023 guidance generally supports calibrating re-testing frequency to baseline fibrosis burden.[3] Patients with LSM below roughly 7.0 kPa and well-controlled metabolic risk factors can often extend to a 24-month interval. Those in the roughly 8.0 to 12.0 kPa range are usually re-tested annually. Patients at roughly 12.0 kPa and above are typically re-tested every 6 to 12 months, especially during active treatment.

MASLD Staging and Resmetirom Prescribing Criteria

MASLD diagnostic criteria

MASLD replaced the older term NAFLD following a 2023 multisociety Delphi consensus.[9] The diagnosis combines evidence of hepatic steatosis (by CAP, other imaging, or biopsy) with at least one cardiometabolic risk factor such as elevated BMI, fasting glucose, blood pressure, triglycerides, or reduced HDL cholesterol. Significant alcohol intake reclassifies the picture as ALD or MetALD rather than MASLD. VCTE functions as a non-invasive screening step that can reduce, but does not eliminate, the need for biopsy in ambiguous cases.

Resmetirom (Rezdiffra): FDA approval, March 2024

Resmetirom is the first FDA-approved pharmacotherapy specifically for MASLD-associated liver fibrosis, approved in March 2024.[10] The FDA-approved prescribing criteria require a VCTE reading of at least 8.2 kPa at screening, combined with biopsy-confirmed MASH and F2-F3 fibrosis. VCTE therefore functions as a gating filter: patients below 8.2 kPa are unlikely to meet the biopsy-based criteria and are not appropriate candidates on VCTE grounds alone at that time. Dosing (80 mg versus 100 mg) is weight-based per the FDA label, taken orally once daily.[10] This is an FDA-approved indication, not an off-label or compounded use, as of the March 2024 label; readers should confirm current label status given that labels can be revised.

GLP-1 and GLP-1/GIP agonists in MASLD: trial evidence, not an approved MASLD indication

As of the underlying trial publications, semaglutide 2.4 mg and tirzepatide were being studied in MASH but semaglutide's approved indications are for weight management and cardiovascular risk reduction, not a standalone MASLD/MASH indication. The ESSENCE trial in biopsy-confirmed MASH with F2-F3 fibrosis reported that a substantially higher proportion of semaglutide-treated patients achieved MASH resolution without worsening fibrosis compared with placebo, with liver stiffness reduction as a pre-specified secondary endpoint.[12] This is trial evidence describing an investigational use in this population; it should not be read as an FDA-approved MASLD indication unless the label has since changed, which readers should verify against current FDA labeling before treating it as settled.

What "Optimal" Means Versus "Normal"

"Normal" means below the disease threshold used by a guideline. "Optimal," a term used more in longevity-oriented practice than in guideline documents, generally means tracking toward the low end of what's seen in metabolically healthy people rather than simply staying under a disease cutoff.

A population-based study using paired VCTE data in adults without liver disease or known metabolic syndrome reported a median liver stiffness in the high-4 to low-5 kPa range for middle-aged adults.[13] That range is a reasonable reference point for a "low normal" target in a metabolically healthy patient undergoing elective monitoring, though it is a population median, not a treatment target validated by an interventional trial, and a reader should not treat it as a number to chase at the expense of overinterpreting normal biological variation.

Testosterone replacement therapy and liver stiffness

At physiologic replacement doses delivered by injectable or transdermal routes, testosterone therapy has not been shown in the literature reviewed here to worsen liver stiffness.[14] Oral 17-alpha-alkylated androgens are a distinct and separately hepatotoxic category and are not part of evidence-based TRT protocols. Because metabolic syndrome and MASLD co-occur frequently in patients seeking TRT, a patient on TRT with baseline MASLD still warrants routine VCTE monitoring on the same schedule as any other MASLD patient at that fibrosis stage, and this recommendation reflects site judgment about monitoring cadence rather than a specific guideline statement about TRT and VCTE together.

FIB-4 plus VCTE as a sequential pathway

EASL's non-invasive test guidance describes a two-step approach: FIB-4 as an inexpensive first-pass filter, followed by VCTE for patients whose FIB-4 falls in the indeterminate zone (roughly 1.30 to 2.67).[2] AASLD's 2023 guidance describes a broadly similar sequential approach, noting that combining FIB-4 with VCTE meaningfully improves classification accuracy compared with either test alone in the indeterminate zone; a reader who needs the exact reclassification percentage reported in that guidance document should confirm the figure against the original publication rather than a paraphrase.[3] A FIB-4 below 1.30 in a patient under 65 has a high negative predictive value for advanced fibrosis and can sometimes allow VCTE to be deferred; a FIB-4 at or above 2.67 generally warrants direct VCTE and hepatology referral regardless of age.

A Practical Monitoring Protocol

Baseline assessment

Before the first VCTE: a fasting lipid panel, fasting glucose and HbA1c, ALT and AST, platelet count (for FIB-4), and BMI. Calculate FIB-4. If FIB-4 is at or above roughly 1.30, proceed to VCTE. If FIB-4 is below 1.30 in a patient under 65 with no red-flag symptoms, an annual FIB-4 re-check is a reasonable default before deciding whether VCTE is needed.

The exam should follow a 2-hour fast, with the patient resting supine for about 10 minutes beforehand. The IQR/M ratio should be documented with every result, and any exam with IQR/M at or above 0.30 should be flagged and repeated.

Monitoring schedule by stage

F0-F1 (LSM below roughly 7.0 kPa) with stable metabolic risk factors: repeat at 24 months. F2 (roughly 8.0-12.0 kPa): repeat at 12 months with concurrent FIB-4 and ALT review. F3 (roughly 12.0 kPa and above): repeat every 6-12 months, refer to hepatology, and discuss resmetirom candidacy and biopsy planning if not already done. F4 (roughly 13.0-15.0 kPa and above): hepatology-led care, VCTE every 6 months, and HCC surveillance with ultrasound and AFP on a schedule set by the hepatology team.[3]

Interpreting a falling kPa during GLP-1 therapy

A patient who loses substantial body weight over several months on a GLP-1 receptor agonist may show a meaningful liver stiffness reduction at the next VCTE. Whether that reflects true fibrosis regression or mainly reduced steatosis and hepatic congestion is genuinely uncertain from a single follow-up exam. A sustained reduction of roughly 30% or more across two consecutive annual exams, alongside normalized ALT and improving FIB-4, is more consistent with genuine fibrosis regression than a single favorable scan, and that sustained pattern, rather than one good result, is the more defensible basis for reducing monitoring frequency.

Evidence boundary: what is established, what is plausible, what is not established

Established: VCTE-derived kPa correlates with biopsy fibrosis stage across multiple validation cohorts, and guideline bodies use broadly similar (though not identical) kPa thresholds for staging MASLD-related fibrosis. IQR/M below 0.30 is a recognized validity requirement. Resmetirom is FDA-approved for biopsy-confirmed MASH with F2-F3 fibrosis, with a VCTE screening floor of 8.2 kPa specified in the label, as of the March 2024 approval.

Plausible but not fully proven at the individual-patient level: that a 20% rise or 30% fall in serial VCTE, on its own, reliably predicts an individual patient's biopsy-confirmed fibrosis trajectory. These thresholds come from guideline consensus and trial-level associations between LSM change and biopsy change in groups, not from a validated individual-patient prediction rule.

Not established from the sources reviewed here: a single universal cirrhosis-detection AUROC or a single universal percentage for how much a specific drug's trial changed fibrosis outcomes; these numbers vary by study, probe, and population, and a reader who needs a precise figure for a specific decision should pull it from the original publication rather than a secondary summary, including this one.

VCTE does not replace biopsy when biopsy confirmation is specifically required by a drug's label, and it does not substitute for urgent evaluation if a patient develops signs of decompensated liver disease, such as jaundice, ascites, confusion, or gastrointestinal bleeding, which warrant urgent care rather than routine elastography follow-up.